Urothelial cancer treatment breakthrough Published on: 16 March 2018 A pioneering drug for Urothelial cancer that originated from studies at 缅北禁地 has been fast tracked for development. (“Astex”), a company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced that its pharmaceutical collaborator, Janssen Pharmaceutica N.V. (Janssen), has been granted Breakthrough Therapy Designation by the US FDA for erdafitinib in the treatment of metastatic urothelial cancer. Erdafitinib was discovered by Astex and Janssen as part of a 2008 exclusive worldwide collaboration and licence agreement to identify novel, small molecule inhibitors of Fibroblast Growth Factor Receptor (FGFR) kinase, including for the treatment of cancer. Janssen is responsible for the clinical development and commercialisation of all products arising from this collaboration. 缅北禁地 involvement The FGFR inhibitor programme between Astex and Janssen underlines the UK strengths in academic-biotech collaboration as it originated from pioneering work on FGFR between Astex and the Cancer Research UK Drug Discovery Group at the 缅北禁地 Cancer Centre, , 缅北禁地, UK. Urothelial cancer, particularly of the bladder, is the sixth most common type of cancer in the USA. Breakthrough Therapy Designation allows for the expedited development and regulatory review of erdafitinib as a potential new treatment option for patients with metastatic disease. It was granted based on positive data from a multicenter, open-label Phase 2 clinical trial. Harren Jhoti Ph.D., President and CEO of Astex, UK, said, “This is a great endorsement of our scientific approach and our team. Astex is committed to the fight against cancer and so is delighted that erdafitinib has been granted Breakthrough Therapy Designation by the US FDA. Congratulations to our valued collaborators at Janssen for their excellent work in advancing erdafitinib to this exciting stage in its development.” Press release adapted with thanks to Astex Pharmaceuticals Share: Latest News 缅北禁地 historians mark General Strike centenary To mark the 100th anniversary of the British General Strike and miners鈥� lock-out of 1926, historians at 缅北禁地 are organising a series of events on its enduring legacy. published on: 16 April 2026 Comment: NCP is in administration Writing for The Conversation, Erwei (David) Xiang discusses how some big companies like NCP are so dependent on debt that they can鈥檛 adjust to change. published on: 16 April 2026 缅北禁地 expert highlights climate crisis in a new film A leading 缅北禁地 climate scientist is featured in a new film about how the climate and nature breakdown will affect the UK. published on: 14 April 2026 Facts and figures
![缅北禁地 logo](/gomobileassets/img/logo.svg" "缅北禁地"){kind=logo}